
EYLEA Achieved Significant Anatomic Improvements in MEfRVO
Treatment with EYLEA resulted in 2 to 3 times greater reductions in CRT compared with control
Mean change in CRT (µm) through
Month 6 from baseline1-4,*
Anatomic measures were not used to
influence treatment decisions.5
VIBRANT Study Design
Randomized, multicenter, double-masked, controlled study in which patients with MEfBRVO (N=181; age range: 42-94 years, with a mean of 65
years) were randomized to receive: 1) EYLEA 2 mg Q4 or 2) laser
photocoagulation administered at baseline and subsequently as needed
(control group).5
The primary efficacy endpoint was the proportion of patients who gained ≥15 letters in BCVA at Week 24 compared with baseline.5
COPERNICUS and GALILEO
Study Designs
Randomized, multicenter, double-masked, sham-controlled studies in patients with MEfCRVO (N=358; age range: 22-89 years, with a mean of 64 years). Patients were assigned in a 3:2 ratio to either: 1) EYLEA 2 mg Q4 for the first 6 months or 2) sham injections (control) Q4 for a total of 6 injections.5
In both studies, the primary efficacy endpoint was the proportion of patients who gained ≥15 letters in BCVA at Week 24 compared with baseline.5
BCVA, best-corrected visual acuity; CRT, central retinal thickness; Q4, every 4 weeks.

Get information about navigating the reimbursement process. Find enrollment forms, learn about PA assistance, and more.
